English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/8837
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 211 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar EndNote (RIS)Exportar EndNote (RIS)
Título

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

Autor Harari, Alexandre; Bart, Pierre-Alexandre; Stöhr, Wolfgang; Tapia, Gonzalo; García Cabezas, Miguel Ángel; Medjitna-Rais, Emmanuelle; Burnet, Séverine; Cellerai, Cristina; Erlwein, Otto; Barber, Tristan; Moog, Christiane; Liljeström, Peter; Wagner, Ralf; Wolf, Hans; Kraehenbuhl, Jean-Pierre; Esteban, Mariano; Heeney, Jonathan L.; Frachette, Marie-Joelle; Tartaglia, James; McCormack, Sheena; Babiker, Abdel; Weber, Jonathan; Pantaleo, Giuseppe
Palabras clave EuroVacc 02 clinical trial
New York vaccinia virus (NYVAC)
Human immunodeficiency virus (HIV)-1
T-cell immune response
DNA C plus NYVAC C vaccine
HIV vaccines
Fecha de publicación 14-ene-2008
EditorRockefeller University Press
Citación The Journal of Experimental Medicine 205(1): 63-77 (2008)
ResumenThe EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen comprising recombinant DNA and the poxvirus vector NYVAC, both expressing a common immunogen consisting of Env, Gag, Pol, and Nef polypeptide domain from human immunodeficiency virus (HIV)-1 clade C isolate, CN54. 40 volunteers were randomized to receive DNA C or nothing on day 0 and at week 4, followed by NYVAC C at weeks 20 and 24. The primary immunogenicity endpoints were measured at weeks 26 and 28 by the quantification of T cell responses using the interferon enzyme-linked immunospot assay. Our results indicate that the DNA C plus NYVAC C vaccine regimen was highly immunogenic, as indicated by the detection of T cell responses in 90% of vaccinees and was superior to responses induced by NYVAC C alone (33% of responders). The vaccine-induced T cell responses were (a) vigorous in the case of the env response (mean 480 spot-forming units/106 mononuclear cells at weeks 26/28), (b) polyfunctional for both CD4 and CD8 T cell responses, (c) broad (the average number of epitopes was 4.2 per responder), and (d) durable (T cell responses were present in 70% of vaccinees at week 72). The vaccine-induced T cell responses were strongest and most frequently directed against Env (91% of vaccines), but smaller responses against Gag-Pol-Nef were also observed in 48% of vaccinees. These results support the development of the poxvirus platform in the HIV vaccine field and the further clinical development of the DNA C plus NYVAC C vaccine regimen.
Descripción 15 pages, 8 figures.-- PMID: 18195071 [PubMed].-- PMCID: PMC2234371.
Versión del editorhttp://dx.doi.org/10.1084/jem.20071331
URI http://hdl.handle.net/10261/8837
DOI10.1084/jem.20071331
ISSN0022-1007
Aparece en las colecciones: (CNB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Harari_JExpMed_2008.pdf6,64 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.